This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Reports for ConocoPhillips, Medtronic & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ConocoPhillips (COP), Medtronic plc (MDT) and PayPal Holdings, Inc. (PYPL).
Medtronic (MDT) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $87.10 in the latest trading session, marking a -0.55% move from the prior day.
Stryker (SYK) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 5.63% and 5.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Medtronic (MDT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Medtronic (MDT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $82.58, marking a +0.9% move from the previous day.
ResMed (RMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 3.75% and 3.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $81.20 in the latest trading session, marking a +0.5% move from the prior day.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update
by Zacks Equity Research
Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $79.52, moving +1% from the previous trading session.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $79.85, moving -0.59% from the previous trading session.
Medtronic (MDT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $80.86, moving +1.04% from the previous trading session.
Medtronic (MDT) Stock Moves -1.16%: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $80.03, marking a -1.16% move from the previous day.
Why Is Medtronic (MDT) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Enrolls 1st Patient Trial for Hugo RAS System
by Zacks Equity Research
Medtronic's Hugo RAS system is designed to be used in Expand URO U.S. clinical trial study for urologic surgical procedures.
Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.
Medtronic (MDT) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 1.56% and 1.72%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.
Medtronic (MDT) Stock Moves -0.78%: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $82.90, marking a -0.78% move from the previous day.
IM Cannabis Corp. (IMCC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of 16.67% and 45.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
National Vision (EYE) Q3 Earnings Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 87.50% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Phibro Animal Health (PAHC) Misses Q1 Earnings Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of -19.23% and 3.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?